Ajanta Pharma FDA inspection concludes with Form-483 issuance

Ajanta Pharma US FDA Inspection at Paithan Facility Concludes with Form-483 Issuance. The FDA inspection at Ajanta's Paithan manufacturing facility has concluded with the issuance of a Form-483, indicating minor observations requiring corrective action. Form-483 is a standard regulatory communication and does not constitute a warning letter. The company will need to respond to these observations within the stipulated timeframe.

📊 STOCKS: AJANTAPHARM | 🏢 SECTOR: Pharma | #MEDIUMIMPACT #Compliance